Successful Combined S Systemic-Regional Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma: Report of Two Cases
https://doi.org/10.37174/2587-7593-2022-5-1-83-91
Abstract
We present two patients with advanced unresectable intrahepatic cholangiocarcinoma successfully treated with combined systemic-regional chemotherapy. Intra-arterial treatment included oily chemoembolization and chemoinfusion (GEMOX) with additional systemic chemotherapy (GEMCIS). Chemotherapy did not stop after extrahepatic progression: metastases to the lungs and bones. Continuous symptomatic nutritional support allowed to minimize chemotherapeutic toxicity and to maintain good quality of life. One patient is still alive for more than 4 years, the other died of tumor progression in three years ten months. The importance of factors contributing to the long-term survival of patients with advanced intrahepatic cholangiocarcinoma is considered.
About the Authors
P. G. Tarazov
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Russian Federation
Russian Federation
197758, Saint Petersburg, p. Pesochny, Leningradskaya str., 70
T. I. Kagacheva
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Russian Federation
Russian Federation
197758, Saint Petersburg, p. Pesochny, Leningradskaya str., 70
A. A. Polikarpov
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Russian Federation
Russian Federation
197758, Saint Petersburg, p. Pesochny, Leningradskaya str., 70
A. V. Moiseenko
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
Russian Federation
Russian Federation
197758, Saint Petersburg, p. Pesochny, Leningradskaya str., 70
References
1. Dolgushin BI, Virshke ER, Kosyrev VY, et al. Intra-arterial chemoembolization in the treatment of inoperable patients with nodular cholangiocarcinoma. Annals of Surgical Hepatology. 2015;20(3):24-30. (In Russian). DOI: 10.16931/1995-5464.2015324-30.
2. Tarazov PG, Kagacheva TY. Roentgenoendovascular interventions in the treatment of intrahepatic cholangiocarcinoma (review). Diagnostic and Interventional Radiology. 2021;15(3):55-66. (In Russian. DOI: 10.25512/DIR.2021.15.3.06.
3. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepaticartery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2015;111(2):213-20. DOI: 10.1002/jso.23781.
4. Buettner S, Braat AJAT, Margonis GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: A multicenter retrospective analysis. J Vasc Interv Radiol. 2020;31(7):1035-43. E2. DOI: 10.1016/j.jvir.2020.02.008.
5. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2020;6(1):51-9. DOI: 10.1001/jamaoncol.2019.3702.
6. Konstantinidis IT, Koerkamp BG, Do RKG, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer. 2016;122(5):758-65. DOI: 10.1002/cncr.29824.
7. Mosconi C, Solaini L, Vara G, et al. Transarterial chemoembolization and radioembolization for unresectable intrahepatic cholangiocarcinoma — a systemic review and meta-analysis. Cardiovasc. Intervent Radiol. 2021;44(5):728-38. DOI: 10.1007/s00270-021-02800-w
8. Yu Q, Liu C, Pillai A, Ahmed O. Twenty years of radiation therapy of unresectable intrahepatic cholangiocarcinoma: Internal or external? A systematic review and meta-analysis. Liver Cancer. 2021;10(5):433-50. DOI: 10.1159/000516880.
9. Shipilova AN. Medical treatment of biliary cancer. In: Cholangiocellular carcinoma. Zhao AV, ed. GEOTAR-Media, 2021. P. 277-338 (In Russian). DOI: 10.33029/9704-5955-3-CC-2021-1-368.
10. Nooijen LE, Franken LC, Belkouz A, et al. Efficacy and safety of gemcitabine plus cisplatin as potential preoperative chemotherapy in locally advanced intrahepatic, perihilar, and mid-cholangiocarcinoma: A retrospective cohort study. Am J Clin Oncol. 2021;44(10):526-32. DOI: 10.1097/COC.0000000000000861.
11. Ogasawara S, Ooka Y, Koroki K, et al. Switching to systemic therapy after locoregional treatment failure: Definition and best timing (review). Clin Mol Hepatol. 2020;26(2):155-62. DOI: 10.3350/cmb.2019.0021n.
12. Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers. 2021;13(3):558. DOI: 10.3390/cancers13030558.
13. Breder VV, Bazin IS, Kosyrev VY, Ledin E.V. Practical recommendations on medical treatment of biliary cancer. Malignant tumors: Practical recommendations RUSSCO #3s2, 2021:11(26):452-67 (In Russian). DOI: 10.18027/2224-50-57-2021-11-3s2-26.
Review
For citations:
Tarazov P.G., Kagacheva T.I., Polikarpov A.A., Moiseenko A.V. Successful Combined S Systemic-Regional Chemotherapy for Advanced Intrahepatic Cholangiocarcinoma: Report of Two Cases. Journal of oncology: diagnostic radiology and radiotherapy. 2022;5(1):83–91. (In Russ.) https://doi.org/10.37174/2587-7593-2022-5-1-83-91
Views:
381
Email this article 